These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26786094)

  • 1. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma.
    Wang Q; Luan W; Warren L; Kadri H; Kim KW; Goz V; Blank S; Isabel Fiel M; Hiotis SP
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):574-582. PubMed ID: 26786094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.
    Han Q; Wang Y; Pang M; Zhang J
    J Exp Clin Cancer Res; 2017 Nov; 36(1):156. PubMed ID: 29115974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
    J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune hepatic inflammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12.
    Tamaki S; Homma S; Enomoto Y; Komita H; Zeniya M; Ohno T; Toda G
    Clin Immunol; 2005 Dec; 117(3):280-93. PubMed ID: 16246626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
    Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
    Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
    Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.
    Conroy H; Galvin KC; Higgins SC; Mills KH
    Cancer Immunol Immunother; 2012 Mar; 61(3):425-31. PubMed ID: 22193988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of HBsAg gene-modified dendritic cell-based vaccine efficacy by optimizing immunization method or the application of β-glucosylceramide.
    Long J; Zhou B; Li H; Dai Q; Zhang B; Xing S; Zeng Z; Chen W; Yang J
    Immunol Invest; 2013; 42(2):137-55. PubMed ID: 23323523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
    Larmonier N; Marron M; Zeng Y; Cantrell J; Romanoski A; Sepassi M; Thompson S; Chen X; Andreansky S; Katsanis E
    Cancer Immunol Immunother; 2007 Jan; 56(1):48-59. PubMed ID: 16612596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.
    Li X; Zhang Z; Lin G; Gao Y; Yan Z; Yin H; Sun B; Wang F; Zhang H; Chen H; Cao D
    Tumour Biol; 2016 Aug; 37(8):11267-78. PubMed ID: 26951511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study.
    El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA
    Clin Exp Med; 2018 Nov; 18(4):535-546. PubMed ID: 30062618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.
    Liu JY; Wu Y; Zhang XS; Yang JL; Li HL; Mao YQ; Wang Y; Cheng X; Li YQ; Xia JC; Masucci M; Zeng YX
    Cancer Immunol Immunother; 2007 Oct; 56(10):1597-604. PubMed ID: 17440723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
    Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
    Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
    Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
    Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cells, especially ICOS
    Tu JF; Ding YH; Ying XH; Wu FZ; Zhou XM; Zhang DK; Zou H; Ji JS
    Sci Rep; 2016 Oct; 6():35056. PubMed ID: 27725696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic DNA vaccine targeting Foxp3
    Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
    Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
    Vogt A; Sievers E; Lukacs-Kornek V; Decker G; Raskopf E; Meumann N; Büning H; Sauerbruch T; Strassburg CP; Schmidt-Wolf IG; Gonzalez-Carmona MA
    Liver Int; 2014 Mar; 34(3):447-61. PubMed ID: 23998316
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Lurje I; Werner W; Mohr R; Roderburg C; Tacke F; Hammerich L
    Front Immunol; 2021; 12():650486. PubMed ID: 34025657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifuroxazide prompts antitumor immune response of TCL-loaded DC in mice with orthotopically-implanted hepatocarcinoma.
    Zhao T; Jia H; Cheng Q; Xiao Y; Li M; Ren W; Li C; Feng Y; Feng Z; Wang H; Zheng J
    Oncol Rep; 2017 Jun; 37(6):3405-3414. PubMed ID: 28498414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.